Monday, November 17, 2025 at 2-3pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Hepatitis C Virus (HCV) is a virus that replicates in the liver, leading to inflammation of the liver (hepatitis) in the short-term. The acute phase of HCV infection, defined as the first 6 months of infection, is often difficult to diagnose because many patients are asymptomatic. The chronic phase of HCV infection begins when the infection lasts more than 6 months. Chronic HCV is associated with liver fibrosis, which can lead to complications such as cirrhosis and hepatocellular carcinoma (HCC), both of which are associated with substantial morbidity and mortality. While HCV is treatable, it is an underrecognized and underdiagnosed disease.

The patient population infected with HCV tends to consist of younger, marginalized people who often have limited access to screening and diagnosis, including the imprisoned, people who inject drugs (PWID), people living with HIV, and those with high-risk sex practices such as men who have sex with men (MSM). With the development of efficacious HCV treatment regimens, the focus has shifted from meeting unmet medical needs to the broad goals of eliminating HCV infection and improving the HCV care cascade. The World Health Organization (WHO) has set a goal of HCV elimination by 2030, although most states are not on track to reach that goal. Therapies that can treat all genotypes, as well as acute or chronically infected patients with comorbidities, can be used to support HCV elimination. Mavyret (G/P) is a leading direct-acting antiviral (DAA) treatment for HCV that addresses these needs through its well-studied efficacy and safety profile.

Learning Objectives

• Provide an overview of Hepatitis C and the epidemiology of acute and chronic HCV.
• Describe the WHO elimination targets, the progress to date, and action items.
• Outline the most recent American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) guideline recommendations for the treatment of acute and chronic HCV with an HCV treatment landscape overview.
• Review of glecaprevir and pibrentasvir acute HCV clinical data.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.